Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer (MPR-OC): a Prospective, Multicenter Phase II Study (MITO-RT3/RAD)

NCT04593381 is registered in ClinicalTrials.gov with Gemelli Molise Hospital as lead sponsor.

NCT NCT04593381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04593381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer (MPR-OC): a Prospective, Multicenter Phase II Study (MITO-RT3/RAD)
Lead sponsor
Gemelli Molise Hospital
Phase
Not applicable
Overall status
Completed
Start date
March 1, 2021
Completion date
December 31, 2023
Enrollment
376 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic disease, ovarian neoplasms, recurrent ovarian carcinoma